Literature DB >> 25975446

Preoperative therapy for extremity soft tissue sarcomas.

Lara E Davis1, Christopher W Ryan.   

Abstract

OPINION STATEMENT: High-risk soft tissue sarcomas (STS) are defined as large (>5 cm), intermediate/high-grade tumors and can carry a >50 % risk of death from metastases. A regimen of preoperative chemoradiation immediately addresses issues of both local control and micrometastases and should be considered for patients with high-risk STS of the extremities. While acute wound healing complications are more likely to occur, these are most always manageable and reversible, as opposed to the long-term complications associated with higher radiation doses and larger fields required for post-operative therapy. Preoperative treatment also yields potential prognostic information from pathologic treatment response, and quantitative imaging methods hold promise to detect early treatment effect. Definitive evidence of survival benefit from neoadjuvant therapy has been elusive, but a large body of experience has accumulated at dedicated centers where this approach is utilized. Whenever possible, it is imperative that patients with high-risk STS be enrolled on well-designed clinical trials. Treatment planning and administration requires a coordinated multidisciplinary approach that should be undertaken in high-volume centers with expertise in the management of sarcomas.

Entities:  

Mesh:

Year:  2015        PMID: 25975446     DOI: 10.1007/s11864-015-0346-4

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  59 in total

1.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

2.  Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma.

Authors:  Lloyd A Mack; Phil J Crowe; Jia Lin Yang; Norman S Schachar; Don G Morris; Elizabeth C Kurien; Claire L F Temple; Robert L Lindsay; Enzio Magi; William G DeHaas; Walley J Temple
Journal:  Ann Surg Oncol       Date:  2005-06-20       Impact factor: 5.344

3.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.

Authors:  S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

4.  Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

Authors:  Silvia Stacchiotti; Paolo Verderio; Antonella Messina; Carlo Morosi; Paola Collini; Antonio Llombart-Bosch; Javier Martin; Alessandro Comandone; Jurado Cruz; Andrea Ferraro; Giovanni Grignani; Sara Pizzamiglio; Vittorio Quagliuolo; Piero Picci; Sergio Frustaci; Angelo Paolo Dei Tos; Paolo G Casali; Alessandro Gronchi
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

5.  Preoperative multimodality treatment for soft tissue sarcomas.

Authors:  E A Levine; M Trippon; T K Das Gupta
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time.

Authors:  Jürgen Weitz; Christina R Antonescu; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.

Authors:  Christopher W Ryan; Anthony G Montag; Janet R Hosenpud; Brian Samuels; James B Hayden; Arthur Y Hung; Atiya Mansoor; Terrance D Peabody; Arno J Mundt; Samir Undevia
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

9.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Authors:  John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

10.  Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.

Authors:  Janelle M Meyer; Kelly S Perlewitz; James B Hayden; Yee-Cheen Doung; Arthur Y Hung; John T Vetto; Rodney F Pommier; Atiya Mansoor; Brooke R Beckett; Alina Tudorica; Motomi Mori; Megan L Holtorf; Aneela Afzal; William J Woodward; Eve T Rodler; Robin L Jones; Wei Huang; Christopher W Ryan
Journal:  Clin Cancer Res       Date:  2013-10-16       Impact factor: 12.531

View more
  5 in total

Review 1.  Therapeutic options and postoperative wound complications after extremity soft tissue sarcoma resection and postoperative external beam radiotherapy.

Authors:  Mohamed H Abouarab; Iman L Salem; Magdy M Degheidy; Dominic Henn; Christoph Hirche; Ahmad Eweida; Matthias Uhl; Ulrich Kneser; Thomas Kremer
Journal:  Int Wound J       Date:  2017-12-05       Impact factor: 3.315

2.  Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.

Authors:  Alicia A Gingrich; Sarah B Bateni; Arta M Monjazeb; Morgan A Darrow; Steven W Thorpe; Amanda R Kirane; Richard J Bold; Robert J Canter
Journal:  Ann Surg Oncol       Date:  2017-07-24       Impact factor: 5.344

3.  Immediate versus Delayed Sarcoma Reconstruction: Impact on Outcomes.

Authors:  Kyle J Sanniec; Cristine S Velazco; Lyndsey A Bryant; Nan Zhang; William J Casey; Raman C Mahabir; Alanna M Rebecca
Journal:  Sarcoma       Date:  2016-07-13

4.  Preoperative evaluation of the efficacy of radio-hyperthermo-chemotherapy for soft tissue sarcoma in a case series.

Authors:  Hisaki Aiba; Satoshi Yamada; Jun Mizutani; Norio Yamamoto; Hideki Okamoto; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Yoshihiro Araki; Hiroyuki Tsuchiya; Takanobu Otsuka
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

Review 5.  Neoadjuvant Radiotherapy-Related Wound Morbidity in Soft Tissue Sarcoma: Perspectives for Radioprotective Agents.

Authors:  Cameron M Callaghan; M M Hasibuzzaman; Samuel N Rodman; Jessica E Goetz; Kranti A Mapuskar; Michael S Petronek; Emily J Steinbach; Benjamin J Miller; Casey F Pulliam; Mitchell C Coleman; Varun V Monga; Mohammed M Milhem; Douglas R Spitz; Bryan G Allen
Journal:  Cancers (Basel)       Date:  2020-08-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.